C

C. each well. More than 3,300 DAPI-stained cells were examined in each well. The number of TUNEL-positive cells was CPA inhibitor divided by that of DAPI-stained cells to calculate the ratio of TUNEL staining. At least three independent experiments were performed in triplicate. qRT-PCR Total RNA was isolated from the cells using the SV total RNA isolation system (Promega). The cDNA was prepared by a reverse transcription reaction using the SuperScript VILO cDNA synthesis system (Life Technologies). Real-time CPA inhibitor quantitative reverse transcription PCR (qRT-PCR) was performed with a SYBR Premix Ex Taq II kit (Takara) according to the manufacturer’s instructions. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The specific primer sets used were as follows: ATP6V0A3 (TCIRG1), 5-GGC CAC GGG CTG CTC ATG TT-3 and 5-CTG GTG GCG CGA CTG AAG CA-3; ATP6V0A4, 5-TTC AGA CGC Rabbit Polyclonal to Gastrin GAG GCT GGG GA-3 and 5-GTC GCA GGG CGT GCA GGA AA-3; ATP6V1C1, 5-GCA TGC GGC AAC TTC AAA GA-3 and 5-GCC AAC CAA GAC ATC CAA CG-3; Bax, 5-GGC CGG GTT GTC GCC CTT TT-3 and 5-CCG CTC CCG GAG GAA GTC CA-3; Bcl-2, and 5-AAG CTC CCA CCA GGG CCA AA-3; GAPDH, 5-GCA CCG TCA AGG CTG AGA AC-3 and 5-TGG TGA AGA CGC CAG TGG A-3. A melting curve analysis and gel electrophoresis of the PCR products were used to confirm the CPA inhibitor amplification specificity of each primer set. All mRNA expression levels were normalized to that of GAPDH. All experiments were performed in triplicate. Western blot analyses of proteins related to MAPK and apoptosis MISK81-5, SAS, HSC-4 and SQUU-B cells were lysed in lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 2.5 mM sodium pyrophosphate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA and 1% Triton X-100] containing proteinase and phosphatase inhibitors [1 mM phenylmethylsulfonyl fluoride, 1 mM -glycerophaspahate, 1 mM Na3VO4 and 4% protease inhibitor cocktail]. The protein concentration was quantified using a Micro BCA Protein Assay Kit (Thermo, Rockford, IL, USA). CPA inhibitor The protein samples (30 or 40 g/lane) were separated by 10 or 12% SDSCPAGE, and were electrotransferred to Immun-Blot PVDF membranes (Bio-Rad, Hercules, CA, USA). The membranes were probed with primary antibodies for 1 hr and incubated for 1 hr with secondary antibodies conjugated with peroxidase (GE, Buckingham, UK). The primary antibodies against Bax and Bcl-2 were incubated with the membrane overnight at 4C. Chemiluminescent signals were then developed with ECL Prime (GE) and detected using a cooled CCD-camera (LAS-1000, Fujifilm, Tokyo, Japan). Antibodies for phospho-p38 MAPK (pT180/pY182), p38(SAPK2a), phospho-STAT3 (pY705, pS727) and total STAT3 were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Antibodies against Bax and Bcl-2 were obtained from Cell Signaling Technology (Danvers, MA, USA). The antibody for -actin was purchased from Sigma (St. Louis, MO, USA). The procedure was identical to those used in previous study [33]. In the semiquantitative analyses of the levels of protein expression, the CPA inhibitor intensity of the bands was measured using the ImageJ (Image J ver. 1.44, http://rsb.info.nih.gov/ij/index.html) densitometric analysis software program. -actin was used as an internal control protein. The target protein/-actin ratio based on the intensity of the bands was calculated [34]. CMA-induced cytotoxicity in cells treated with siRNA against Bcl-2 in cell culture According to the manufacturer’s protocol, Bcl-2-siRNA (final conc. 20 nM) was transfected into SQUU-B cells using Lipofectamine RNAiMAX (Invitrogen) and Opti-MEM (Invitrogen) [33] in 96-well plates at 24 hr after cell seeding. siRNA for human Bcl-2 (Hs_BCL2_2981) and a universal negative control siRNA (Sigma) were used as a target and negative control, respectively. At 24.